Revenue: EUR4.2 billion for the full year 2024, a 2.6% increase in constant currency. Organic Growth: 2.3% organic growth in H2 2024, reversing part of the decline in H1. Gross Profit: EUR1 billion for the year, with a 77 basis points increase in gross margin to 24.5%. Adjusted EBITA: EUR471 million for the year, a 0.9% increase, with a stable margin of 11.2%. Net Profit: EUR189.5 million, stable compared to the prior year. Free Cash Flow: EUR342 million, impacted by higher working capital investment. Acquisitions: Eight acquisitions completed in 2024, contributing over EUR140 million in 2023 revenues. Net Debt Leverage: Ended the year at 2.9, within the covenant of 4.5. Liquidity Position: EUR804 million in cash and unused credit facilities.

Warning! GuruFocus has detected 7 Warning Sign with AZLGF.

Release Date: February 20, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Azelis Group NV (AZLGF) reported a steady improvement in results throughout 2024, with organic growth turning positive in Q3 and remaining positive in Q4. The company's business model proved resilient, maintaining a stable EBITA margin of 11.2% despite cost inflation. Revenue increased by 4.3% in Q4, with a total revenue of EUR4.2 billion for the full year, marking a 2.6% increase in constant currency. Azelis Group NV (AZLGF) completed eight acquisitions in 2024, contributing to its strategic growth and diversification. The company launched Impact 2030, an ambitious sustainability agenda, and won five industry awards for innovative formulations, highlighting its commitment to innovation and sustainability.

Negative Points

The market remained volatile, with improvements varying across regions and end markets, driven by geopolitical uncertainty. Industrial Chemicals saw a decline of 1.7% for the full year, indicating challenges in this segment. Net profit for the year was stable at EUR189.5 million, showing no significant growth compared to the prior year. Free cash flow conversion decreased to 72.1% in 2024, impacted by higher working capital investments. Leverage increased to 2.9x, approaching the company's covenant limit, which may constrain future M&A activities.

Q & A Highlights

Q: You've signaled that the order book has seen a positive build-up into this first quarter. Should we expect a further improvement in the organic GP growth versus 4Q levels? Also, how do you see gross margins evolving in 2025 if industrials were to come back? A: We have good visibility on the rest of the quarter, and it looks positive. Compared to Q4, there will be an improvement due to seasonality. Regarding gross margins, our diversified portfolio means that the impact will depend on which segments improve. Generally, industrial margins are lower than Life Sciences.

Story Continues

Q: Can you remind us how import tariffs from the US might impact Azelis in terms of sourcing? Also, are you expecting organic growth in Q1 gross profit and earnings? A: We operate a local-for-local business model, so most products are produced in the region where they are sold, minimizing direct impact from tariffs. We expect organic growth to continue in Q1, supported by a positive order book.

Q: How big is your Personal Care and beauty business, and how do you see trends in that market given recent warnings from larger companies? A: Personal Care represents roughly 15% of our global portfolio. We serve smaller, emerging brands that are gaining market share from larger companies, driven by consumer preference for local brands.

Q: Could you give an indication of how much further you have to run on portfolio optimization initiatives by region? A: Portfolio optimization is ongoing, particularly in emerging markets and areas where we have done M&A. We estimate an annual revenue impact of EUR20 million to EUR30 million, mainly in Asia and Latin America.

Q: Regarding APAC margins, what else do you need to achieve similar margins to other regions? Also, can you provide details on the M&A spend in 2024? A: Achieving similar margins in APAC involves gaining scale and improving portfolio maturity. In 2024, M&A spend was EUR295 million, with EUR135 million for new acquisitions and EUR165 million for deferred payments and minority buyouts.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments